Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs.
about
Molecularly targeted therapy for the treatment of head and neck cancer: a review of the ErbB family inhibitorsSpotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectivesGenomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumorsToxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trialsSulindac compounds facilitate the cytotoxicity of β-lapachone by up-regulation of NAD(P)H quinone oxidoreductase in human lung cancer cellsCardiovascular toxicity of multi-tyrosine kinase inhibitors in advanced solid tumors: a population-based observational studyReal-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients.Sunitinib-associated hypertension and neutropenia as efficacy biomarkers in metastatic renal cell carcinoma patientsAnti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.The current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma.Generation and characterization of a human nanobody against VEGFR-2.Evaluating the role of treatment-related toxicities in the challenges facing targeted therapies for advanced hepatocellular carcinoma.Biological toxicities as surrogate markers of efficacy in patients treated with mTOR inhibitors for metastatic renal cell carcinoma.A phase II study of axitinib in advanced neuroendocrine tumors.Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapiesMolecular Targeted Therapy in Modern Oncology: Imaging Assessment of Treatment Response and Toxicities.Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes.Key pathways and genes controlling the development and progression of clear cell renal cell carcinoma (ccRCC) based on gene set enrichment analysis.Molecular markers to predict clinical outcome and radiation induced toxicity in lung cancerCardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval).The many facets of PEDF in drug discovery and disease: a diamond in the rough or split personality disorder?Can a treatment be licenced on the basis of post-treatment predictive biomarkers?Current adjuvant therapeutic approaches for pancreatic cancer.The changing landscape of phase I trials in oncology.Safety of monoclonal antibodies and related therapeutic proteins for the treatment of neovascular macular degeneration: addressing outstanding issues.Management of poor-risk metastatic renal cell carcinoma: current approaches, the role of temsirolimus and future directions.Long-term response to sunitinib: everolimus treatment in metastatic clear cell renal cell carcinoma.Safety of available treatment options for renal cell carcinoma.Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas.Identification of clinical biomarkers for patients with advanced hepatocellular carcinoma receiving sorafenib.Adverse events of monoclonal antibodies used for cancer therapy.Is Treatment-Emergent Toxicity a Biomarker of Efficacy of Apatinib in Gastric Cancer?Severe toxicity caused by sorafenib in hepatocellular carcinoma match the data from renal cell carcinoma.Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma.Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study.A robust two-stage design identifying the optimal biological dose for phase I/II clinical trials.
P2860
Q26750719-ACD669E0-6DE9-403F-A924-FCCD13D0DB8CQ26751274-C0C72033-EBAB-424D-B026-E5EEB59EF03DQ26998790-A185F319-69D0-484A-A9E9-A8D801F0922DQ28067583-8C8E39BD-AE62-46DE-85EA-11B442FAB711Q28539534-EF472413-C7B1-4E78-B0D8-1D25BAFEC46BQ28545130-0A21479D-19B0-4D4A-990A-44A47B5BE30EQ33422376-788ABCE1-2460-4359-A7CD-7059E6AC5559Q33426958-5CADAEE8-6B00-4121-B071-9515DA76CBBFQ33770680-61DE4F8D-29A3-4EE9-B0CB-F50D90B568ACQ34365135-369B336A-6384-460A-B7D4-DEBA18EDF320Q34523277-55D96056-D90F-4452-B6D7-13DCFB5277B9Q35739362-5330E660-AF3D-44AC-B5F0-235B0FD72689Q36243104-01663231-674C-40F7-BF5A-C159CE723BA3Q37131421-13DA43E6-1F1E-47CD-8241-56C040C1E691Q37438970-718F39BF-B6FE-4E5D-8F3B-A0AB2CF3CA4AQ37589551-637E21E2-46E1-4230-A3EA-8332AFE0EEF7Q37621799-FCADBF90-B4C2-4B9F-98DC-9B5F34D1100FQ37639475-4FF99F38-7626-48C2-B1A2-812A0DF24A96Q37670436-16B7E8B8-BDEC-446A-8BF3-10BBB6C124D3Q38101883-1AFF42C5-85F6-4236-B3B5-600A657EE346Q38103913-DC3851F8-15EC-4D17-ACC4-9B9B94C0C53BQ38210285-79FC82E3-11F4-4E14-ABCF-FBD794C3F745Q38321245-6A50D297-5EB5-4F06-909E-74CDB805BE52Q38629203-244EA05B-4168-4DB4-978F-EEA32F8C9DABQ38633532-E86E74CE-0529-4CD6-B5E5-3C80A526126AQ38647604-D7F6D0EF-39C2-4882-9399-85F347D0337DQ38823987-DB2444B4-93F2-4201-BC81-EF810111BC2AQ38824719-D904A791-DCCD-423F-AF4D-D047532E85A2Q38930166-01205E65-9D09-43F7-BE9E-A4E8983FE2D6Q39473582-710AE602-3199-4FD4-A7AB-A2B07CFE2A38Q40812370-0E5818C0-3CA2-4119-B6EE-CC198D84A302Q42336244-A1BAC54C-DDE2-4C50-AC36-AF7D46DEB9E3Q42581249-2F04F606-46F9-4841-926F-596BEA45FBBBQ47123004-32F7298A-E3C2-42E2-858E-51B74924053FQ47888326-0FC0F3F8-4265-41E0-A995-5DB8ED434272Q55069897-DECD20A7-9E81-4D0C-8E87-9015727B12B0
P2860
Toxicity as a biomarker of efficacy of molecular targeted therapies: focus on EGFR and VEGF inhibiting anticancer drugs.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Toxicity as a biomarker of eff ...... F inhibiting anticancer drugs.
@en
Toxicity as a biomarker of eff ...... F inhibiting anticancer drugs.
@nl
type
label
Toxicity as a biomarker of eff ...... F inhibiting anticancer drugs.
@en
Toxicity as a biomarker of eff ...... F inhibiting anticancer drugs.
@nl
prefLabel
Toxicity as a biomarker of eff ...... F inhibiting anticancer drugs.
@en
Toxicity as a biomarker of eff ...... F inhibiting anticancer drugs.
@nl
P2093
P2860
P1433
P1476
Toxicity as a biomarker of eff ...... F inhibiting anticancer drugs.
@en
P2093
Irene Braña
Jordi Rodon
Rodrigo Dienstmann
P2860
P304
P356
10.1634/THEONCOLOGIST.2011-0163
P577
2011-12-01T00:00:00Z